A translational stop in the hepatitis B virus (HBV) precore codon 28 and specific changes in the core promoter region of the X gene have been suggested to influence the level of circulating HBeAg in patients. We analysed the core promoter region and precore sequences from 59 HBV strains (including 14 from the databank) of different genotypes and from patients with different HBeAg/anti-HBe patterns. The initiator and TATA elements for transcription of precore and pregenomic RNA were highly conserved. The majority of X gene deletions in the core promoter region would lead to translational frame-shifts and stops, truncating the Cterminal end of the X protein. We found significant associations between specific changes in core promoter positions 1762 to 1764, or in precore codon 28, and absence of circulating HBeAg. For the core promoter mutations alone, this association was
Introduction
The X gene is the smallest of the four, partially overlapping open reading frames (ORFs) of the hepatitis B virus (HBV) genome. It codes for a 154-amino-acid polypeptide designated HBxAg or X protein (Rossner, 1992) . The X gene was the last of the HBV genes to be characterized, is thought to be an early gene (Wu et al., 1991) and has been hypothesized to be of cellular origin (Miller & Robinson, 1986) . The main function of the X protein is as a transcriptional activator and it has been shown to transactivate a number of cellular and viral promoters (Rossner, 1992) .
At the downstream (3h) end of the X ORF lies the core promoter. Until recently, the core promoter was poorly Author for correspondence : Karin Kidd-Ljunggren (mail should be sent to address 2). Fax j46 46 137414. e-mail Karin. Kidd!infek.lu.se related to the apparent degree of liver damage (as estimated by alanine aminotransferase levels) at the time of sampling. Mutations at nucleotides 1762 and/or 1764 were often accompanied by point mutations at positions 1751 to 1755. Since mutations at nucleotide positions 1762 and 1764 have recently been shown by in vitro studies to suppress HBeAg production with a concomitant enhancement of virus production, disappearance of the HBeAgpositive phenotype associated with 1762 to 1764 mutations may thus have at least as much significance for the course of infection as HBeAg absence associated with precore codon 28 stop mutations. These observations are considered against a secondary structural model for the 3h end of HBV pregenomic RNA which also predicts enhancement of virus replication after mutation at positions 1762 and 1764.
defined, but was thought to span approximately 108 nucleotides (Yuh et al., 1992) (positions 1742 to 1849 according to the numbering of Okamoto et al., 1988 ; Fig. 1 ). This region not only directs the transcription of precore\core sequences, but is also essential for the production of pregenomic RNA (Siddiqui, 1991) , which is some 30 bases shorter than precore mRNA. The most indispensable elements of the core promoter were recently defined by Chen et al. (1995) and found to coincide with the start of precore mRNA. The core promoter region contains DR1, one of the two repeat sequences which are essential for primer binding during the complex process of genome replication (Ganem & Varmus, 1987) . The region of the X gene encompassing the core promoter encodes that part of the X protein which is believed to be important for transactivation (Arii et al., 1992 ; Takada et al., 1994 ; Takada & Koike, 1994 ; .
Ever since the discovery of HBV e-antigen (HBeAg) by Magnius & Espmark (1972) , its function has remained an enigma. Initially believed to be the main infectivity marker in Fig. 1 . The hepatitis B virus core promoter, positioned at the downstream end of the X gene (nucleotide numbering by Okamoto et al., 1988) . The transcription initiation sites for precore RNA and pregenomic RNA are depicted by long arrows. The positions of DR1 (direct repeat 1) and TA4 [the minimal sequence necessary for transcription initiation of both precore and pregenomic RNA as described by Chen et al. (1995) ] are shown. The position of amino acid 132 from the second Kunitz domain-like region of the X protein is also indicated.
HBV infection, its role has been suggested more recently to be as an inducer of immunological tolerance (Milich et al., 1990) . HBeAg is secreted after cleavage from a 212-amino-acid precursor, precore protein, which may have a negative regulatory role in virus replication (Lambert et al., 1993 ; Guidotti et al., 1996) .
There is still no certain knowledge about the events which lead to seroconversion from HBeAg to anti-HBe status, but a strong contender has been a mutation in precore codon 28 which leads to a translational stop and thereby prevents the expression of HBeAg (Carman et al., 1989 ; Tong et al., 1990 ; Takeda et al., 1990) . A large number of studies of this mutation have been published (reviewed by Feitelson, 1994) .
A more recent but also convincing theory for the loss of HBeAg in patient serum is that specific changes in the core promoter region, and positions 1762 and 1764 in particular, might prevent transcription of the precore region and thus prevent translation and HBeAg formation Sato et al., 1995) . However, the indispensable core promoter initiator and TATA elements are located downstream of nucleotide positions 1762 to 1764 (Chen et al., 1995) . A recent in vitro study by Buckwold et al. (1996) nevertheless showed that after mutation of these positions, the core promoter could no longer bind a liverenriched transcription factor. Transcription of precore RNA and consequently expression of HBeAg were found to be reduced to approximately one-third of wild-type levels, while levels of other transcripts were unaffected.
In order to consider the role of core promoter sequence changes in the apparent loss of HBeAg circulation, and to compare the relative importance of those changes with that of the stop mutation commonly seen in precore codon 28, we have investigated the possible associations between either core promoter sequence identity or precore codon 28 identity, and HBeAg\anti-HBe status. Analysis of sequences covering the core promoter and the precore gene from the four main HBV genotypes in relation to the patient's condition and HBeAg status was done for 45 patients. Consideration of genotype here has enabled us to differentiate core promoter nucleotide variation as a result of long-term virus evolution from that arising through evolution of strains within genotypes.
Methods
HBV strains. Virus strains from 45 chronic HBV-carriers, representing genotypes A, B, C and D, were studied. The patients had various degrees of liver damage. Their HBeAg and anti-HBe status is indicated in Table 1 . In addition, 14 HBV strains from the databank (identified here by their databank accession number) were incorporated into the study. These strains were chosen on the basis of the HBeAg\anti-HBeAg status of the patients being stated, either in the GenBank accession notes, or published elsewhere (Table 1) . Alanine aminotransferase (ALT) levels above twice the normal value were considered as indicative of liver damage, as were ALT levels above 1n5 times the normal value if accompanied by evidence of chronic active hepatitis, cirrhosis or hepatocellular carcinoma from liver biopsy. For the analysis of so-called core promoter deletions, published sequences with deletions were also selected (Repp et al., 1992 ; Horikita et al., 1994 ; Laskus et al., 1994 ; Okamoto et al., 1994 ; Barlet et al., 1994 ; Uchida et al., 1995 ; Gotoh et al., 1995) . The HBeAg\anti-HBe status and genotype or subtype were not available for some of the published sequences.
Results
The last 97 nucleotides of the X gene and the adjoining precore gene of 45 well-defined HBV strains were determined. These were analysed together with 14 databank sequences where the HBeAg\anti-HBe status of the patient was defined. Table 1 shows a breakdown of the strains in terms of genotype and HBeAg\anti-HBe status of the patient at the time of sampling. Genotypes A to D were represented. Thirty-seven patients had circulating HBeAg and 22 lacked HBeAg.
DNA sequences of the core promoter region
The last 97 nucleotides of the X gene constitute all but the last 11 nucleotides of the core promoter, or basal core promoter as originally defined (Yuh et al., 1992) . Two highly conserved regions were found, spanning nucleotides 1776 to 1798 (no variations between strains), and 1812 to 1837 (variations in, at most, one of 59 strains at any position) (Fig. 2) . The upstream conserved region codes for a part of the X protein that is required for its transactivation activity (Takada et al., 1994) . The first conserved region includes the 11 nucleotide overlapping initiator and TATA box of the core promoter (nucleotides 1788 to 1798 ; Chen et al., 1995) .
There are two variable regions in the core promoter region (nucleotides 1751 to 1775, and 1799 to 1811) (Fig. 2) . The first region is hypervariable, and includes the previously described variable positions 1762 and 1764 . Very few changes appear to be genotype-specific. The G to A change at position 1757 appears to be largely genotype Dspecific, and the C to T change often seen at position 1773 was encountered only once in a genotype C strain. In the second variable region, CG at positions 1802 to 1803 in place of TT appears to be entirely characteristic of all genotype A and D strains.
Correlation of changes at positions 1762 and 1764 with HBeAg status
As previously described , nucleotide 1762 can be either A or T, and nucleotide 1764 can be G or A (Fig. 2) . This variation appears to be independent of genotype, but none of our six genotype A strains deviated from the consensus A"('#GG"('% sequence. In some genotype D strains displaying variability at these two positions, there was a T instead of G or A at position 1764. The pattern emerging for nucleotide identity at positions 1762 and 1764 strongly suggests a correlation with HBeAg\anti-HBe phenotypic expression (Fig. 2) . The presence of the sequence A"('#GG"('% was significantly associated with HBeAg positivity and simultaneous anti-HBe negativity (Chi-square test with Yates' correction ; P 0n0001). All six strains with aberrant HBeAg\ anti-HBe status, i.e. positive for both markers or negative for both markers, had a non-AGG motif at positions 1762 to 1764. With respect to HBeAg\anti-HBe status and the sequence of precore codon 28, the wild-type sequence (as opposed to a stop codon) correlated with the presence of HBeAg and simultaneous absence of anti-HBe with equal significance to the core promoter association (P 0n0001). Only three of 33 HBeAg-positive\anti-HBe-negative samples showed a stop in precore codon 28, whereas 19 of 26 samples not displaying that marker combination had a stop.
According to the above correlations, 12 cases did not have the nucleotide (1762 and 1764) sequence to be expected from their respective HBeAg\anti-HBe status. The patient and strain characteristics of these cases are shown in Table 2 . The wild-type AGG sequence (usually correlated with HBeAgpositivity) was seen in four HBeAg-negative patients with anti-HBe (strains 24, 25, b and c). Three of them were longstanding symptom-free carriers with normal ALT levels and a translational stop in precore codon 28. The fourth patient (strain 25) had acute, reactivated hepatitis B and displayed a precore wild-type sequence. He was followed sequentially for several years. Six months after the episode of reactivated hepatitis, both his serology and the core promoter and precore sequences of his infecting strain were unchanged. After an additional 6 months he became PCR negative and has remained so for 4 years. Two HBeAg-positive patients harboured strains (31 and 43, in both cases belonging to genotype D) with core promoter mutations and wild-type precore sequences 3 to 6 months before seroconverting to anti-HBe. [Conversely, in two genotype A strains (4 and 6), no core promoter changes Fig. 2 . Alignment of core promoter sequences from 59 HBV sequences. The top line is a wild type consensus sequence using nucleotide numbering by Okamoto et al. (1988) . Dots represent nucleotides identical to the consensus sequence and deletions are hyphenated. The accession numbers of the databank strains (a to n) are : a (D23677), b (D23678), c (D23679), d (D23680), e (D23681), f (X04615), g (D12980), h (D23682), i (D23683), j (D23684), k (L08806), l (M32138), m (L27106), n (X59795).
were seen in HBeAg-positive samples despite impending seroconversion to anti-HBe (data not shown).] In three cases, samples from HBeAg-positive patients with high ALT levels (9, 16 and 22) showed wild-type precore sequences but had changes in core promoter nucleotides 1762 and 1764 (Table 2) .
Association of changes at positions 1762 and 1764 with liver damage
We found a significant association between liver damage (as reflected by elevated ALT levels and\or liver histology as defined in Methods) and absence of an intact AGG motif (non- AGG) at positions 1762 to 1764 (P l 0n003). No such association was found between liver disease and the precore codon 28 stop mutation.
Association of changes at positions 1751 to 1755 with liver damage
We then considered whether other mutations in the two variable regions of the so-called core promoter might have an association with liver damage. The second hypervariable region (positions 1799 to 1811) was discounted, firstly because of the genotype-specificity of the linked nucleotide 1802\1803 mutations, and because of the heterogeneity seen amongst the few other mutations encountered. With regard to the first variable region (positions 1751 to 1775), we analysed mutations upstream of position 1762 and downstream of position 1764 as two separate blocks.
Positions 1766, 1768, 1773 and 1775 would thus constitute one block. When analysed as such, there was no significant association between the presence of one or more mutations (relative to the consensus) and liver disease as reflected by high ALT levels.
Deviations from the consensus sequence at any of the positions 1751 to 1755 were then analysed for possible association with liver damage. (Since the G to A change at position 1757 is largely genotype D-specific, it was ignored for this comparison. Similarly, the mutations at positions 1747 and 1761 were discounted as each mutation was shown by only one strain.) For positions 1751 to 1755, the presence of at least one point mutation relative to the consensus was significantly associated with liver disease as defined above (P l 0n006). A comparison of the occurrence of at least one mutation at positions 1751 to 1755 with the occurrence of at least one mutation at positions 1762 and 1764, however, showed that a non-A"('#GG"('% (mutated) sequence is likely to be accompanied by at least one point mutation in positions 1751 to 1755 (P l 0n002). With the exception of A"(&# to G, seen in four genotype B strains, all other mutations at positions 1751 to 1755 would be stem-disrupting mutations according to a recent model for the folding of pregenomic RNA put forward by us (Kidd & Kidd-Ljunggren, 1996) (Fig. 3) .
X protein variation
The majority of the so-called core promoter changes shown in Fig. 2 would lead to amino acid alterations in the X protein.
Thus, lysine-130 (specified by nucleotides 1761 to 1763) is commonly substituted by methionine, and valine-131 by isoleucine as a result of the changes in nucleotides 1762 and 1764 described above. In an attempt to map the regions of the X protein necessary for transactivation, Arii et al. (1992) found that phenylalanine-132, cysteine-137 and histidine-139 were all essential. Residues 137 and 139 were found here to be invariant amongst the 59 strains. Phenylalanine-132 (specified by nucleotides 1767 to 1769), was sometimes within a deleted region (see below), but only showed mutation (to tyrosine, which has similar properties) in four cases. Very few nucleotide changes were seen and no significant changes in amino acid properties predicted at the downstream end of the X gene region which overlaps with the start of the precore region (nucleotides 1814 to 1838).
Deletions
Within a region of 30 nucleotides in the core promoter (1748 to 1777) deletions were seen in three of our 45 HBV strains and in two of the 14 databank strains. Additional reports of core promoter deletions exist in the literature (Repp et al., 1992 ; Horikita et al., 1994 ; Laskus et al., 1994 ; Okamoto et al., 1994 ; Barlet et al., 1994 ; Uchida et al., 1995 ; Gotoh et al., 1995) which we also include in Fig. 4 . At least 13 deletions have been described, including deletion number 4 originating from this study. In all cases, phenylalanine-132 is deleted or changed (Fig. 4 b) and in ten cases cysteine-137 and histidine-139, also found to be essential for transactivation (Arii et al., 1992) , are removed through truncation of the protein. No deletions were seen in strains known to be of genotype A. There was no correlation between deletions and HBeAg\anti-HBe status, as all possible constellations of HBeAg and antiHBe could be seen in strains with deletions in the core promoter. The only obvious common factor for the patients was chronic carriership.
In all cases but three (deletions 2, 6 and 9 in Fig. 4) , the deletions would lead to frame-shifts and a translational stop. The resulting X protein would thus be truncated by 19 to 24 amino acids at its C-terminal end. Nine of the ten truncated X Fig. 3 . Predicted folding of part of pregenomic RNA (nt 1742 to 1847) by the program MFOLD. This figure is adapted from Kidd & Kidd-Ljunggren (1996) , but is based here on a consensus sequence for genotype B and C strains. (a) Different reported deletions in the core promoter, and (b) the resulting predicted amino acid sequence with a translational stop indicated by an asterisk. We found deletions type 1, 3 and 4 among our 45 strains. Horikita et al. (1994) reported deletions type 1 and 2. Laskus et al. (1994) described deletions type 1, 3, 5 and 6. Okamoto et al. (1994) found type 1, 8, 9 and 10. Both Uchida et al. (1995) and Gotoh et al. (1995) found deletion type 7. Barlet et al (1994) reported a family where deletions type 1, 11, 12 and 13 were seen, and Repp et al. (1992) found deletion type 1 in a chronic carrier child.
proteins would have -RL as the C terminus, and in seven cases the C-terminal sequence would be -TRRL or -IRRL.
Discussion
Studies such as this which set out to investigate associations between virus nucleotide changes and phenotypic expression in patients require to be interpreted with caution. Neither a necessarily long-term longitudinal study of few patients nor a cross-sectional study of many patients at a particular timepoint in disease can be expected to be definitive, and each approach complements the other. In this study, we set out to determine if core promoter changes could be linked to the presence or absence of HBeAg in serum, and if so, how this association compared in the same patients with the already well-known association of precore codon 28 stop mutation with absence of circulating HBeAg (Tong et al., 1990) . Our cross-sectional approach allowed us to ensure that all major phylogenetic groups of HBV were included in the comparison, which in turn allowed us to exclude global HBV variation from analysis of strain differences.
We found equally significant evidence for the association of HBeAg positivity with a core promoter A"('#GG"('% sequence as for HBeAg positivity and wild-type precore codon 28. This contrasts sharply with the results of Takahashi et al. (1995) , who only found an association between precore codon 28 sequences and HBeAg positivity in Japanese HBV carriers. The reason for this discrepancy is not clear, especially as the latter observation also contrasts with the results of another Japanese group who were the first to describe an association between core promoter 1762 to 1764 mutations and HBeAg negativity.
With regard to our own results, the association found between HBeAg positivity and an AGG motif at positions 1762 to 1764 was remarkable (P 0n0001). Whether the changes in the core promoter precede seroconversion or not can only be assessed by studying consecutive samples from several patients during seroconversion. An indication that this is the case was provided by the genotype D strains with core promoter mutations found in two patients 3 to 6 months before seroconversion from HBeAg positive to anti-HBe (Table 2) .
In vitro experiments by Buckwold et al. (1996) have indicated that precore mRNA production and consequently HBeAg levels are reduced by a factor of 3 when positions 1762 to 1764 are mutated to TGA, probably as a result of reduced transcription factor binding. In contrast, virus production was found to increase as a result of the mutations. Since the precursor of HBeAg, precore protein, is known to inhibit HBV replication (Lambert et al., 1993 ; Guidotti et al., 1996) , one explanation for increased virus replication with T"('#GA"('% is the reduced intracellular level of precore protein. However, it is not clear how the combination of increased virus production and concomitant reduction in the levels of HBeAg secretion found in vitro relate to the absence of detectable HBeAg in patient serum associated with a non-AGG motif. Shutoff of circulating HBeAg is often preceded by high ALT levels, an observation compatible with increased virus replication in vivo.
The effect of a codon 28 stop mutation, in addition to causing truncation of precore mRNA translation products, has similarly been proposed to benefit virus replication through stabilization of encapsidation (Li et al., 1993 ; Lok et al., 1994) .
If TGA at positions 1762 to 1764 does indeed lead to increased virus production in vivo, the virus may be under considerable immunological pressure to down-regulate antigen production even further. It may be that a precore codon 28 mutant can arise at any time during infection, but may be most likely to proliferate when the virus is under attack from the immune system in response to increased replication. A scenario where the one mutation creates circumstances under which mutants at another genomic location are favoured will be difficult to test experimentally.
The core promoter change from A"('#GG"('% to TGA may not only have a bearing on the HBeAg\anti-HBe phenotype, but also on the function(s) of the X protein. These changes convert the amino acid sequence K"$!V"$" to M"$!I"$". The wild-type sequence is part of a region which confers a serine protease inhibitor function on the X protein (Takada & Koike, 1994 ; Takada et al., 1994) , and which has been suggested to be important for the transcriptional transactivation activity (Arii et al., 1992 ). An X protein carrying M"$!I"$" may function less well, but clearly variants with some capacity to replicate can arise, even although this region of the protein is missing entirely, or both altered appreciably and truncated (Fig. 4 b) . Defective X gene deletion mutants could depend for their survival on co-existence with virus expressing wild-type X protein.
The X gene deletions differ from those described in the pre-S2 region by usually leading to frame-shifts, whereas pre-S2 deletions always encompass multiples of three (Feitelson, 1994 ; Yamamoto et al., 1994 ; Kidd-Ljunggren et al., 1995 b) . A currently favoured explanation for the pre-S2 deletions is that of a virus ' escape ' mechanism, as immunodominant epitopes (Itoh et al., 1986) are often deleted, thereby favouring the virus. No such explanation for the deletions in the X gene can be put forward. It is interesting to note in this context that there is a similarity between the C terminus of most truncated HBV X proteins (Fig. 4 b) and the X protein of woodchuck hepatitis virus (WHV). WHV X protein ends with RLL in strains WHV 1 to WHV 4, and with RLP in strain WHV 5 (Rossner, 1992) .
If alterations near the C terminus of X protein effected through mutation in the core promoter region (either single or multiple amino acid changes, or truncation) do have a detrimental effect on the functioning of the X protein, there must surely be a replicative advantage at another level. Upregulation of transcription, changes in post-transcriptional processing and up-regulation of genome replication are all possibilities. Only the effects of mutations at positions 1762 to 1764 have been investigated in vitro (see above), and from this, up-regulation of genome replication appears to be the most likely advantage (Buckwold et al., 1996) .
Although reduced levels of precore protein as a result of 1762 to 1764 mutation may explain increased virus replication (see above), there is at least one other possibility. Consideration of our recent RNA secondary structure model for the immediate environment of DR1 (Kidd & Kidd-Ljunggren, 1996) suggests that mutations 1751 to 1755 and 1762 to 1764 have importance at the level of reverse transcription. According to the model, the wild-type A"('#GG"('% motif stabilizes DR1, but creates a brake to reverse transcription by providing three primer-binding nucleotides in DR1 rather than four (Fig. 3 a) . Mutation of position(s) 1762 and\or 1764 would expose four primer-binding positions in DR1 (Fig. 3 b) . Further mutations in positions 1751 to 1755 would enable the basal stem structure to open more easily for reverse transcription. The core promoter deletions could be predicted to have a similar function, i.e. to reduce the amount of basepairing in the basal stem and facilitate reverse transcription (Kidd & Kidd-Ljunggren, 1996) .
In summary, we have found that a non-AGG motif at positions 1762 to 1764 is significantly linked to the HBeAgnegative phenotype and to increased liver damage as measured by elevated ALT levels. Additionally, after discounting genotypic variability, the non-AGG motif is significantly linked to changes in at least one of the positions 1751 to 1755, which are also associated with elevated ALT levels.
Thus, contrary to what was previously proposed , recent in vitro experiments (Buckwold et al., 1996) and our observations from this cross-sectional study suggest that the absence of an AGG motif at positions 1762 to 1764 increases the replication competence of the HBV strain. Mutation to TGA, AGA or AGT may encourage (but may not be necessary for) the emergence of codon 28 mutants by triggering an upsurge in virus replication in the liver. The virus may be under considerable immunological pressure to downregulate HBeAg levels further at this time. However, exactly when the seroconversion from HBeAg to anti-HBe occurs in a patient may depend on many factors relating, for example, to the replication characteristics of the individual HBV strain and the genetic predisposition of the immune system of the patient.
